NASDAQ:CVAC CureVac (CVAC) Stock Price, News & Analysis $3.72 +0.08 (+2.20%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$3.60▼$3.7450-Day Range$3.06▼$4.9952-Week Range$2.21▼$10.14Volume333,729 shsAverage Volume1.04 million shsMarket Capitalization$832.83 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get CureVac alerts: Email Address CureVac MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside168.8% Upside$10.00 Price TargetShort InterestBearish8.04% of Float Sold ShortDividend StrengthN/ASustainability-1.86Upright™ Environmental ScoreNews Sentiment0.54Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom $0.07 to ($0.49) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.93 out of 5 starsMedical Sector427th out of 936 stocksPharmaceutical Preparations Industry195th out of 436 stocks 3.0 Analyst's Opinion Consensus RatingCureVac has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 3 hold ratings, and 1 sell rating.Amount of Analyst CoverageCureVac has only been the subject of 1 research reports in the past 90 days.Read more about CureVac's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.04% of the float of CureVac has been sold short.Short Interest Ratio / Days to CoverCureVac has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in CureVac has recently increased by 22.79%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCureVac does not currently pay a dividend.Dividend GrowthCureVac does not have a long track record of dividend growth. Previous Next 4.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCureVac has received a 80.46% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "mRNA vaccines" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for CureVac is -1.86. Previous Next 2.5 News and Social Media Coverage News SentimentCureVac has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for CureVac this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for CVAC on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat Follows4 people have added CureVac to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CureVac insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.15% of the stock of CureVac is held by insiders.Percentage Held by InstitutionsOnly 17.26% of the stock of CureVac is held by institutions.Read more about CureVac's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for CureVac are expected to decrease in the coming year, from $0.07 to ($0.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CureVac is -2.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CureVac is -2.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioCureVac has a PEG Ratio of 1.88. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioCureVac has a P/B Ratio of 1.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about CureVac's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. About CureVac Stock (NASDAQ:CVAC)CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company also develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.Read More CVAC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CVAC Stock News HeadlinesJuly 22, 2024 | finance.yahoo.comCVAC Aug 2024 2.000 put (CVAC240816P00002000)July 18, 2024 | americanbankingnews.comCureVac (NASDAQ:CVAC) Shares Gap Down to $3.60July 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 11, 2024 | businesswire.comAgomab Bolsters Executive Team with Appointment of Pierre Kemula as Chief Financial OfficerJuly 4, 2024 | seekingalpha.comCureVac: GSK's Deal For Infectious Disease Assets Is A Long-Shot For Both PharmasJuly 3, 2024 | investorplace.comCureVac Layoffs 2024: What to Know About the Latest CVAC Job CutsJuly 3, 2024 | barrons.comGSK Will Pay Up to $1.5 Billion for CureVac's mRNA VaccinesJuly 3, 2024 | investorplace.comCVAC Stock Alert: CureVac Pops on Licensing Deal With GSKJuly 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 3, 2024 | reuters.comGSK buys full rights to make COVID, influenza vaccines from CureVacMay 26, 2024 | finance.yahoo.comCureVac N.V. (NASDAQ:CVAC) Just Released Its First-Quarter Results And Analysts Are Updating Their EstimatesMay 25, 2024 | finance.yahoo.comCureVac First Quarter 2024 Earnings: Misses ExpectationsMay 24, 2024 | markets.businessinsider.comBuy Rating on CureVac: Positive Financial Outlook and Promising Vaccine Trials Fuel OptimismMay 24, 2024 | seekingalpha.comCureVac: Remains A Hold Based On Bird Flu Vaccine And Oncology AdvancementsMay 23, 2024 | markets.businessinsider.comEQS-News: CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business UpdateMay 23, 2024 | finance.yahoo.comCureVac Announces Financial Results for the First Quarter of 2024 and Provides Business UpdateMay 22, 2024 | msn.comModerna, CureVac, other vaccine stocks jump as new human bird-flu cases reported in U.S., AustraliaMay 22, 2024 | msn.comModerna, BioNTech close with double-digit percentage gains amid bird flu fearsSee More Headlines Receive CVAC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CureVac and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/23/2024Today7/26/2024Next Earnings (Estimated)8/15/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CVAC CUSIPN/A CIK1809122 Webwww.curevac.com Phone49-70-71988-30Fax49-7071-9883Employees1,172Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$18.00 Low Stock Price Target$4.00 Potential Upside/Downside+171.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.33) Trailing P/E RatioN/A Forward P/E Ratio52.71 P/E Growth1.88Net Income$-281,580,000.00 Net Margins-463.49% Pretax Margin-462.44% Return on Equity-49.22% Return on Assets-33.85% Debt Debt-to-Equity Ratio0.08 Current Ratio2.25 Quick Ratio2.09 Sales & Book Value Annual Sales$59.00 million Price / Sales14.00 Cash FlowN/A Price / Cash FlowN/A Book Value$2.50 per share Price / Book1.48Miscellaneous Outstanding Shares223,880,000Free Float219,067,000Market Cap$826.12 million OptionableOptionable Beta2.64 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Alexander Zehnder M.B.A. (Age 54)M.D., CEO, MD & Member of Management Board Comp: $1.05MMr. Pierre Kemula B.Sc. (Age 49)MD, CFO & Member of Management Board Comp: $700.97kDr. Malte Greune Ph.D. (Age 59)COO, Member of Management Board & MD Comp: $643.71kDr. Myriam Mendila M.D. (Age 58)Chief Development Officer, MD & Member of the Management Board Comp: $658.44kDr. Ulrike Gnad-Vogt M.D. (Age 51)Ph.D., Senior VP & Area Head of Oncology Comp: $304.47kDr. Sarah FakihVice President Corporate Communications & Investor RelationsMr. Marco Rau L.L.M.Ph.D., General CounselMr. Thorsten SchullerHead of Corporate CommunicationsSlavica Stevanovic-HeckHead of Human ResourcesDr. Patrick BaumhofSenior Vice President of TechnologyMore ExecutivesKey CompetitorsHUTCHMEDNASDAQ:HCMMerusNASDAQ:MRUSIDEAYA BiosciencesNASDAQ:IDYATG TherapeuticsNASDAQ:TGTXAmicus TherapeuticsNASDAQ:FOLDView All CompetitorsInstitutional OwnershipBank of New York Mellon CorpBought 15,804 shares on 7/26/2024Ownership: 0.007%RA Capital Management L.P.Sold 778,563 shares on 5/17/2024Ownership: 0.878%Tidal Investments LLCBought 57,625 shares on 5/17/2024Ownership: 0.026%Platinum Investment Management Ltd.Bought 128,778 shares on 5/14/2024Ownership: 0.280%China Universal Asset Management Co. Ltd.Bought 17,132 shares on 4/29/2024Ownership: 0.019%View All Institutional Transactions CVAC Stock Analysis - Frequently Asked Questions How have CVAC shares performed this year? CureVac's stock was trading at $4.21 on January 1st, 2024. Since then, CVAC stock has decreased by 11.6% and is now trading at $3.72. View the best growth stocks for 2024 here. How were CureVac's earnings last quarter? CureVac (NASDAQ:CVAC) announced its quarterly earnings data on Thursday, May, 23rd. The company reported ($0.34) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by $0.12. The firm earned $13.43 million during the quarter, compared to analyst estimates of $14.51 million. CureVac had a negative net margin of 463.49% and a negative trailing twelve-month return on equity of 49.22%. When did CureVac IPO? CureVac (CVAC) raised $200 million in an IPO on Friday, August 14th 2020. The company issued 13,300,000 shares at $14.00-$16.00 per share. BofA Securities, Jefferies and Credit Suisse served as the underwriters for the IPO and Berenberg and Kempen were co-managers. Who are CureVac's major shareholders? Top institutional investors of CureVac include Bank of New York Mellon Corp (0.01%). How do I buy shares of CureVac? Shares of CVAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of CureVac own? Based on aggregate information from My MarketBeat watchlists, some other companies that CureVac investors own include Moderna (MRNA), Tesla (TSLA), Novavax (NVAX), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Pfizer (PFE) and This page (NASDAQ:CVAC) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CureVac Please log in to your account or sign up in order to add this asset to your watchlist. Share CureVac With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CVAC Stock Alerts